Chlodantane

Chlodantane (ADK-910), the para-chlorobenzoyl amide of 2-aminoadamantane, is an experimental actoprotector and synthetic adaptogen developed at the Zakusov State Institute of Pharmacology of the Russian Academy of Medical Sciences during an extensive structure-activity campaign that screened 329 novel adamantane derivatives for resistance-enhancing properties in rodent stress models [1, 2]. The compound emerged alongside bromantane (N-(2-adamantyl)-N-(para-bromophenyl)amine) as one of two lead adamantane-derived actoprotectors from the Morozov laboratory program; however, whereas bromantane proceeded to clinical registration in Russia as Ladasten for the treatment of neurasthenia, chlodantane was never advanced to human studies and remains an exclusively preclinical research compound.

Structurally, chlodantane differs from bromantane in the nature of the bond connecting the adamantane cage to the halogenated aromatic ring. Bromantane is a secondary amine (N-(2-adamantyl)-N-(4-bromophenyl)amine), whereas chlodantane is an amide (N-(2-adamantyl)-4-chlorobenzamide), a distinction that alters conformational flexibility, hydrogen-bonding capacity, metabolic susceptibility, and physicochemical behavior [1]. The chlorine-for-bromine halogen substitution is a secondary modification. These combined structural differences produce a pharmacological profile that the primary literature describes as exhibiting a broader adaptogenic activity spectrum than bromantane, with efficacy against hypoxia, hypothermia, hyperthermia, toxic chemical exposure, and other extreme environmental stressors observable after a single administration, a property not characteristic of classical plant-derived adaptogens that typically require repeated dosing over days to weeks [2, 3].

The mechanism of action has not been fully elucidated. The available evidence, derived entirely from animal and cell-culture experiments, points to membrane stabilization as a principal contributor. Chlodantane increases the stability of cell membranes against unfavorable conditions, achieved in part through suppression of overactivated lipid peroxidation (LPO) processes [2, 3]. The adamantane cage, a rigid tricyclo[3.3.1.1(3,7)]decane skeleton with high lipophilicity, partitions into lipid bilayers and interacts with the polar headgroup region of phospholipid membranes, a property shared across the broader adamantane pharmacological class and formally characterized in molecular dynamics simulations of amantadine and memantine in model bilayers [4, 5]. The immunostimulant activity of chlodantane is reported to be more pronounced than that of bromantane, with efficacy in secondary stress-induced immunodeficiency models, though the molecular targets mediating this effect have not been identified [1, 2].

No human pharmacokinetic, efficacy, or safety data exist for chlodantane. The pharmacokinetic profile is inferred from the structurally related bromantane, which displays moderate oral bioavailability (approximately 42 percent), a plasma elimination half-life of approximately 11 hours, hepatic hydroxylation of the adamantane ring as the principal metabolic pathway, and wide tissue distribution driven by the lipophilicity of the adamantane core [6, 7]. Whether the amide bond in chlodantane introduces additional metabolic liabilities (amide hydrolysis, different ring-hydroxylation regioselectivity) relative to the amine bond in bromantane has not been characterized. The compound is not approved for medical use in any jurisdiction and is not listed on any national pharmacopoeia. It is available as a research-grade preparation from limited specialty chemical suppliers at purities stated as greater than 98 percent. Investigators should obtain independent analytical confirmation of identity, purity, and stereochemical composition on every lot. This monograph reviews the chemistry, synthesis, and structural pharmacology of chlodantane; the available preclinical evidence for adaptogenic, actoprotective, antioxidant, and immunostimulant activity; the inferred pharmacokinetics; sourcing and quality considerations; and a comparative assessment of five actoprotector and adaptogenic candidates against chlodantane on five competency standards.